Biomimetic implant for orthopedic surgery

脊柱植入物是一项重要的全球业务，收入为65亿美元（2009年）。虽然目前的合成技术已经证明了临床上的成功，但今天的现实是，这些植入物远不如天然骨。最近，对性能与自体移植物一样好或更好的合成骨移植物的研究已经加强，但还没有产品达到自体骨移植物（即从患者髂嵴采集的骨）的突出程度，因此自体移植物仍然主导市场。 该项目的目标是开发一种工程生物材料，模仿天然骨的所有有益特性，避免痛苦的骨采集过程。该技术将在一系列新的脊柱产品中实施-这是工业赞助商Octane Orthobiologics Inc.的核心专业领域。拟定的动物工作旨在规定和确认材料性能。 这项技术的独特之处在于，天然骨的四个关键属性将首次在全合成生物材料中复制。这一成就将产生第一种合成骨生物材料，其性能与天然骨的黄金标准没有区别，同时避免了与天然来源组织相关的风险。 最终的结果将是一个合成的和可定制的仿生植入物，将匹配或超过天然骨组织的性能。

Spinal implants represent a significant global business with revenues at US$6.5B (2009). While current synthetic technologies have demonstrated clinical success, today's reality is that these implants are far inferior to natural bone. Recently, the search for a synthetic bone graft that performs as well or better than autograft has intensified, but no product has yet to reach the prominence of autologous bone grafts (i.e. bone harvested from patient's iliac crest) and consequently autograft still dominates the market. The objective of this project is to develop an engineered biomaterial that emulates all the beneficial properties of natural bone and avoids the painful bone harvest procedure. The technology will be implemented in an array of new spinal products - a core area of expertise of the industrial sponsor, Octane Orthobiologics Inc. The animal work proposed is to specify and validate material performance. The proposed technology is unique in that the four key attributes of natural bone will be replicated for the first time in a fully synthetic biomaterial. This achievement will result in the first synthetic bone biomaterial that has a performance indistinguishable from the gold standard of natural bone, while simultaneously avoiding the risks associated with naturally sourced tissues. The net result will be a synthetic and customizable biomimetic implant that will match or exceed the performance of natural bone tissue.